CD8
5'-Nucleotidase
/ immunology
Aged
Aged, 80 and over
CD8-Positive T-Lymphocytes
/ immunology
Cell Proliferation
/ physiology
Female
GPI-Linked Proteins
/ immunology
Head and Neck Neoplasms
/ immunology
Humans
Immune Tolerance
/ immunology
Lymphocyte Activation
/ immunology
Lymphocytes, Tumor-Infiltrating
/ immunology
Male
Middle Aged
Tumor Microenvironment
/ immunology
CD73
T cells
head and neck cancer
Journal
European journal of immunology
ISSN: 1521-4141
Titre abrégé: Eur J Immunol
Pays: Germany
ID NLM: 1273201
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
11
03
2020
revised:
07
05
2020
accepted:
15
06
2020
pubmed:
18
6
2020
medline:
30
1
2021
entrez:
18
6
2020
Statut:
ppublish
Résumé
Recent studies have implicated a role for adenosine-dependent immunosuppression in head and neck tumor microenvironments. We describe expression of CD73, an enzyme critical to the generation of adenosine from extracellular AMP, in T cells and other cell types within human head and neck tumors. Flow cytometric analyses of tumor-infiltrating cells indicate that CD3
Identifiants
pubmed: 32548862
doi: 10.1002/eji.202048626
doi:
Substances chimiques
GPI-Linked Proteins
0
5'-Nucleotidase
EC 3.1.3.5
NT5E protein, human
EC 3.1.3.5
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
2055-2066Informations de copyright
© 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Références
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A. and Jemal, A., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. 2018. 68: 394-424.
Pulte, D. and Brenner, H., Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist 2010. 15: 994-1001.
Chow, L. Q. M., Haddad, R., Gupta, S., Mahipal, A., Mehra, R., Tahara, M., Berger, R. et al., Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. J. Clin. Oncol. 2016. 34: 3838-3845.
Ferris, R. L., Immunology and Immunotherapy of Head and Neck Cancer. J. Clin. Oncol. 2015. 33: 3293-3304.
Ferris, R. L., Blumenschein, G., Jr., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K. et al., Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N. Engl. J. Med. 2016. 375: 1856-1867.
Ribas, A., Shin, D. S., Zaretsky, J., Frederiksen, J., Cornish, A., Avramis, E., Seja, E. et al., PD-1 Blockade Expands Intratumoral Memory T Cells. Cancer Immunol. Res. 2016. 4: 194-203.
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J., Robert, L., Chmielowski, B. et al., PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014. 515: 568-571.
Whiteside, T. L., Immunobiology and immunotherapy of head and neck cancer. Curr. Oncol. Rep. 2001. 3: 46-55.
Whiteside, T. L., Immunobiology of head and neck cancer. Cancer Metastasis Rev. 2005. 24: 95-105.
Regateiro, F. S., Cobbold, S. P. and Waldmann, H., CD73 and adenosine generation in the creation of regulatory microenvironments. Clin. Exp. Immunol. 2013. 171: 1-7.
Allard, B., Beavis, P. A., Darcy, P. K. and Stagg, J., Immunosuppressive activities of adenosine in cancer. Curr. Opin. Pharmacol. 2016. 29: 7-16.
Allard, D., Chrobak, P., Allard, B., Messaoudi, N. and Stagg, J., Targeting the CD73-adenosine axis in immuno-oncology. Immunol. Lett. 2018.
Whiteside, T. L., Targeting adenosine in cancer immunotherapy: a review of recent progress. Expert Rev. Anticancer. Ther. 2017. 17: 527-535.
Azambuja, J. H., Ludwig, N., Braganhol, E. and Whiteside, T. L., Inhibition of the Adenosinergic Pathway in Cancer Rejuvenates Innate and Adaptive Immunity. Int. J. Mol. Sci. 2019. 20: 5698.
Erdmann, A. A., Gao, Z. G., Jung, U., Foley, J., Borenstein, T., Jacobson, K. A. and Fowler, D. H., Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo. Blood 2005. 105: 4707-4714.
Hoskin, D. W., Mader, J. S., Furlong, S. J., Conrad, D. M. and Blay, J., Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review). Int. J. Oncol. 2008. 32: 527-535.
Huang, S., Apasov, S., Koshiba, M. and Sitkovsky, M., Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood 1997. 90: 1600-1610.
Lappas, C. M., Rieger, J. M. and Linden, J., A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells. J Immunol. 2005. 174: 1073-1080.
Mastelic-Gavillet, B., Navarro Rodrigo, B., Decombaz, L., Wang, H., Ercolano, G., Ahmed, R., Lozano, L. E. et al., Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8(+) T cells. J. Immunother. Cancer 2019. 7: 257.
Zhang, H., Conrad, D. M., Butler, J. J., Zhao, C., Blay, J. and Hoskin, D. W., Adenosine acts through A2 receptors to inhibit IL-2-induced tyrosine phosphorylation of STAT5 in T lymphocytes: role of cyclic adenosine 3',5'-monophosphate and phosphatases. J Immunol 2004. 173: 932-944.
Allard, D., Allard, B., Gaudreau, P. O., Chrobak, P. and Stagg, J., CD73-adenosine: a next-generation target in immuno-oncology. Immunotherapy 2016. 8: 145-163.
Ohta, A., A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment. Front Immunol. 2016. 7: 109.
Ren, Z. H., Lin, C. Z., Cao, W., Yang, R., Lu, W., Liu, Z. Q., Chen, Y. M. et al., CD73 is associated with poor prognosis in HNSCC. Oncotarget 2016. 7: 61690-61702.
Ren, Z. H., Yuan, Y. X., Ji, T. and Zhang, C. P., CD73 as a novel marker for poor prognosis of oral squamous cell carcinoma. Oncol. Lett. 2016. 12: 556-562.
Deng, W. W., Li, Y. C., Ma, S. R., Mao, L., Yu, G. T., Bu, L. L., Kulkarni, A. B. et al., Specific blockade CD73 alters the ‘exhausted’ phenotype of T cells in head and neck squamous cell carcinoma. Int. J. Cancer 2018. 143: 1494-1504.
Ma, S. R., Deng, W. W., Liu, J. F., Mao, L., Yu, G. T., Bu, L. L., Kulkarni, A. B. et al., Blockade of adenosine A2A receptor enhances CD8(+) T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma. Mol. Cancer 2017. 16: 99.
Chen, D. S. and Mellman, I., Elements of cancer immunity and the cancer-immune set point. Nature 2017. 541: 321-330.
Herbst, R. S., Soria, J. C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A. et al., Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014. 515: 563-567.
Kmiecik, J., Poli, A., Brons, N. H., Waha, A., Eide, G. E., Enger, P. O., Zimmer, J. and Chekenya, M., Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. J. Neuroimmunol. 2013. 264: 71-83.
Piersma, S. J., Jordanova, E. S., van Poelgeest, M. I., Kwappenberg, K. M., van der Hulst, J. M., Drijfhout, J. W., Melief, C. J. et al., High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res. 2007. 67: 354-361.
Sudo, T., Nishida, R., Kawahara, A., Saisho, K., Mimori, K., Yamada, A., Mizoguchi, A. et al., Clinical Impact of Tumor-Infiltrating Lymphocytes in Esophageal Squamous Cell Carcinoma. Ann. Surg. Oncol. 2017. 24: 3763-3770.
Yu, Y., Zeng, D., Ou, Q., Liu, S., Li, A., Chen, Y., Lin, D. et al., Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. JAMA Netw. Open. 2019. 2: e196879.
Balermpas, P., Rodel, F., Weiss, C., Rodel, C. and Fokas, E., Tumor-infiltrating lymphocytes favor the response to chemoradiotherapy of head and neck cancer. Oncoimmunology 2014. 3: e27403.
De Meulenaere, A., Vermassen, T., Aspeslagh, S., Zwaenepoel, K., Deron, P., Duprez, F., Rottey, S. and Ferdinande, L., Prognostic markers in oropharyngeal squamous cell carcinoma: focus on CD70 and tumour infiltrating lymphocytes. Pathology 2017. 49: 397-404.
Fang, J., Li, X., Ma, D., Liu, X., Chen, Y., Wang, Y., Lui, V. W. Y. et al., Prognostic significance of tumor infiltrating immune cells in oral squamous cell carcinoma. BMC Cancer 2017. 17: 375.
Held, W., Siddiqui, I., Schaeuble, K. and Speiser, D. E., Intratumoral CD8(+) T cells with stem cell-like properties: Implications for cancer immunotherapy. Sci Transl Med. 2019. 11: eaay6863.
Im, S. J., Hashimoto, M., Gerner, M. Y., Lee, J., Kissick, H. T., Burger, M. C., Shan, Q. et al., Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 2016. 537: 417-421.
Siddiqui, I., Schaeuble, K., Chennupati, V., Fuertes Marraco, S. A., Calderon-Copete, S., Pais Ferreira, D., Carmona, S. J. et al., Intratumoral Tcf1(+)PD-1(+)CD8(+) T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy. Immunity 2019. 50: 195-211 e110.
Chen, S., Fan, J., Zhang, M., Qin, L., Dominguez, D., Long, A., Wang, G. et al., CD73 expression on effector T cells sustained by TGF-beta facilitates tumor resistance to anti-4-1BB/CD137 therapy. Nat. Commun. 2019. 10: 150.
Lu, J., Chen, X. M., Huang, H. R., Zhao, F. P., Wang, F., Liu, X. and Li, X. P., Detailed analysis of inflammatory cell infiltration and the prognostic impact on nasopharyngeal carcinoma. Head Neck 2018. 40: 1245-1253.
Cossarizza, A., Chang, H. D., Radbruch, A., Acs, A., Adam, A., Adam-Klages, S., Agace, W. et al., Guidelines for the use of flow cytometry and cell sorting in immunological studies. Eur. J. Immunol. 2019. 49: 1457-1973.
Panigrahi, S., Freeman, M. L., Funderburg, N. T., Mudd, J. C., Younes, S. A., Sieg, S. F., Zidar, D. et al., SIV/SHIV Infection Triggers Vascular Inflammation, Diminished Expression of Kruppel-like Factor 2 and Endothelial Dysfunction. J. Infect. Dis. 2016. 213: 1419-1427.